ABIN359926
antibody from antibodies-online
Targeting: RET
CDHF12, CDHR16, HSCR1, MEN2A, MEN2B, MTC1, PTC, RET51
Antibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN359926 - Provider product page
- Provider
- antibodies-online
- Product name
- anti-Ret Proto-Oncogene (RET) (AA 21-51), (N-Term) antibody
- Antibody type
- Polyclonal
- Description
- Protein G column, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS
- Reactivity
- Human
- Host
- Rabbit
- Epitope
- AA 21-51, N-Term
- Vial size
- 0.4 mL
- Storage
- Store undiluted at 2-8°C for one month or (in aliquots) at-20°C for longer.
- Handling
- Avoid repeated freezing and thawing.
Submitted references Intronic single nucleotide polymorphisms in the RET protooncogene are associated with a subset of apparently sporadic pheochromocytoma and may modulate age of onset.
The tyrosine phosphatase Shp-2 mediates intracellular signaling initiated by Ret mutants.
A novel germ-line point mutation in RET exon 8 (Gly(533)Cys) in a large kindred with familial medullary thyroid carcinoma.
BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC.
McWhinney SR, Boru G, Binkley PK, Peczkowska M, Januszewicz AA, Neumann HP, Eng C
The Journal of clinical endocrinology and metabolism 2003 Oct;88(10):4911-6
The Journal of clinical endocrinology and metabolism 2003 Oct;88(10):4911-6
The tyrosine phosphatase Shp-2 mediates intracellular signaling initiated by Ret mutants.
D'Alessio A, Califano D, Incoronato M, Santelli G, Florio T, Schettini G, Carlomagno MS, Cerchia L, de Franciscis V
Endocrinology 2003 Oct;144(10):4298-305
Endocrinology 2003 Oct;144(10):4298-305
A novel germ-line point mutation in RET exon 8 (Gly(533)Cys) in a large kindred with familial medullary thyroid carcinoma.
Da Silva AM, Maciel RM, Da Silva MR, Toledo SR, De Carvalho MB, Cerutti JM
The Journal of clinical endocrinology and metabolism 2003 Nov;88(11):5438-43
The Journal of clinical endocrinology and metabolism 2003 Nov;88(11):5438-43
BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC.
Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, Máximo V, Botelho T, Seruca R, Sobrinho-Simões M
Oncogene 2003 Jul 17;22(29):4578-80
Oncogene 2003 Jul 17;22(29):4578-80
No comments: Submit comment
No validations: Submit validation data